Trial Profile
Safety clinical trial and pharmacological evaluation of intravenous administration of CIGB-300 in patients with solid tumors refractory to oncospecific treatment.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 300 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms TS-FARMEV
- 19 Sep 2011 New trial record